Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B K Link

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1994
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapyG J Weiner, S A Kostelny, J R Hillstrom, et al.
International Journal of Cancer|July 31, 2001
Humanization and characterization of the anti-HLA-DR antibody 1D10S A Kostelny, B K Link, J Y Tso, et al.
Journal of Leukocyte Biology|February 24, 2001
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigensB Jahrsdörfer, G Hartmann, E Racila, et al.
Cancer|December 18, 2001
Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of careB K Link, G T Budd, S Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJ M Vose, B K Link, M L Grossbard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatmentT A Davis, A J Grillo-López, C A White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2015
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†C Casulo, B Day, K L Dawson, et al.
Blood Cancer Journal|February 4, 2017
Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemiaJ G Sfeir, M T Drake, B R LaPlant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programP McLaughlin, A J Grillo-López, B K Link, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1994
The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapyG J Weiner, S A Kostelny, J R Hillstrom, et al.
International Journal of Cancer|July 31, 2001
Humanization and characterization of the anti-HLA-DR antibody 1D10S A Kostelny, B K Link, J Y Tso, et al.
Journal of Leukocyte Biology|February 24, 2001
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigensB Jahrsdörfer, G Hartmann, E Racila, et al.
Cancer|December 18, 2001
Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of careB K Link, G T Budd, S Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphomaJ M Vose, B K Link, M L Grossbard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatmentT A Davis, A J Grillo-López, C A White, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2015
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†C Casulo, B Day, K L Dawson, et al.
Blood Cancer Journal|February 4, 2017
Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemiaJ G Sfeir, M T Drake, B R LaPlant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment ProgramP McLaughlin, A J Grillo-López, B K Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programP McLaughlin, A J Grillo-López, B K Link, et al.
Pageof 3